Differential Activation of Pregnane X Receptor and Constitutive Androstane Receptor by Buprenorphine in Primary Human Hepatocytes and HepG2 Cells

Buprenorphine is a partial μ-opioid receptor agonist used for the treatment of opioid dependence that has several advantages over methadone. The principal route of buprenorphine disposition has been well established; however, little is known regarding the potential for buprenorphine to influence the...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The Journal of pharmacology and experimental therapeutics 2010-12, Vol.335 (3), p.562-571
Hauptverfasser: Li, Linhao, Hassan, Hazem E., Tolson, Antonia H., Ferguson, Stephen S., Eddington, Natalie D., Wang, Hongbing
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 571
container_issue 3
container_start_page 562
container_title The Journal of pharmacology and experimental therapeutics
container_volume 335
creator Li, Linhao
Hassan, Hazem E.
Tolson, Antonia H.
Ferguson, Stephen S.
Eddington, Natalie D.
Wang, Hongbing
description Buprenorphine is a partial μ-opioid receptor agonist used for the treatment of opioid dependence that has several advantages over methadone. The principal route of buprenorphine disposition has been well established; however, little is known regarding the potential for buprenorphine to influence the metabolism and clearance of other drugs by affecting the expression of drug-metabolizing enzymes (DMEs). Here, we investigate the effects of buprenorphine on the activation of pregnane X receptor (PXR) and constitutive androstane receptor (CAR), as well as the induction of DMEs, in both HepG2 cells and human primary hepatocytes (HPHs). In HepG2 cells, buprenorphine significantly increased human PXR-mediated CYP2B6 and CYP3A4 reporter activities. CYP2B6 reporter activity was also enhanced by buprenorphine in HepG2 cells cotransfected with a chemical-responsive human CAR variant. Real-time reverse transcription-polymerase chain reaction analysis revealed that buprenorphine strongly induced CYP3A4 expression in both PXR- and CAR-transfected HepG2 cells. However, treatment with the same concentrations of buprenorphine in HPHs resulted in literally no induction of CYP3A4 or CYP2B6 expression. Further studies indicated that buprenorphine could neither translocate human CAR to the nucleus nor activate CYP2B6/CYP3A4 reporter activities in transfected HPHs. Subsequent experiments to determine whether the differential response was due to buprenorphine’s metabolic stability revealed a dramatically differential rate of elimination for buprenorphine between HPHs and HepG2 cells. Taken together, these studies indicate that metabolic stability of buprenorphine defines the differential induction of DMEs observed in HepG2 and HPHs, and the results obtained from PXR and CAR reporter assays in immortalized cell line require cautious interpretation.
doi_str_mv 10.1124/jpet.110.173187
format Article
fullrecord <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2993555</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0022356524461235</els_id><sourcerecordid>20829393</sourcerecordid><originalsourceid>FETCH-LOGICAL-c533t-cea9b5051af39731c2d1f88d631aef456951e46806faea4de646869acffab89e3</originalsourceid><addsrcrecordid>eNp1kc9uEzEQxi0EomnhzA35BZb6z3q7viCFlDZIlYqqInGzJt5x62pjr2wnUh6DN8ZpIIJDT55P8_lnz3yEfODsE-eiPX-asNSqqgvJ-4tXZMaV4A3jTL4mM8aEaKTq1Ak5zfmJMd62nXxLTgTrhZZazsivS-8cJgzFw0jntvgtFB8DjY5-T_gQICD9Se_Q4lRiohAGuoghF1821Yt0HoYUc9nbjqbVjn7ZTBUa0_Toa8eHCvNrSDu63Kwh0CVOUKLdFczPyKqvBV3gOOZ35I2DMeP7P-cZ-XH19X6xbG5ur78t5jeNVVKWxiLolWKKg5O6Dm_FwF3fD53kgK5VnVYc265nnQOEdsCuik6DdQ5WvUZ5Rj4fuNNmtcbB1hUkGM10-KeJ4M3_neAfzUPcGqG1VEpVwPkBYOsCckJ3vMuZ2adj9unUqqrndOqNj_8-efT_jaMa9MGAdfCtx2Sy9RgsDj6hLWaI_kX4bzR7o8I</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Differential Activation of Pregnane X Receptor and Constitutive Androstane Receptor by Buprenorphine in Primary Human Hepatocytes and HepG2 Cells</title><source>MEDLINE</source><source>Alma/SFX Local Collection</source><creator>Li, Linhao ; Hassan, Hazem E. ; Tolson, Antonia H. ; Ferguson, Stephen S. ; Eddington, Natalie D. ; Wang, Hongbing</creator><creatorcontrib>Li, Linhao ; Hassan, Hazem E. ; Tolson, Antonia H. ; Ferguson, Stephen S. ; Eddington, Natalie D. ; Wang, Hongbing</creatorcontrib><description>Buprenorphine is a partial μ-opioid receptor agonist used for the treatment of opioid dependence that has several advantages over methadone. The principal route of buprenorphine disposition has been well established; however, little is known regarding the potential for buprenorphine to influence the metabolism and clearance of other drugs by affecting the expression of drug-metabolizing enzymes (DMEs). Here, we investigate the effects of buprenorphine on the activation of pregnane X receptor (PXR) and constitutive androstane receptor (CAR), as well as the induction of DMEs, in both HepG2 cells and human primary hepatocytes (HPHs). In HepG2 cells, buprenorphine significantly increased human PXR-mediated CYP2B6 and CYP3A4 reporter activities. CYP2B6 reporter activity was also enhanced by buprenorphine in HepG2 cells cotransfected with a chemical-responsive human CAR variant. Real-time reverse transcription-polymerase chain reaction analysis revealed that buprenorphine strongly induced CYP3A4 expression in both PXR- and CAR-transfected HepG2 cells. However, treatment with the same concentrations of buprenorphine in HPHs resulted in literally no induction of CYP3A4 or CYP2B6 expression. Further studies indicated that buprenorphine could neither translocate human CAR to the nucleus nor activate CYP2B6/CYP3A4 reporter activities in transfected HPHs. Subsequent experiments to determine whether the differential response was due to buprenorphine’s metabolic stability revealed a dramatically differential rate of elimination for buprenorphine between HPHs and HepG2 cells. Taken together, these studies indicate that metabolic stability of buprenorphine defines the differential induction of DMEs observed in HepG2 and HPHs, and the results obtained from PXR and CAR reporter assays in immortalized cell line require cautious interpretation.</description><identifier>ISSN: 0022-3565</identifier><identifier>EISSN: 1521-0103</identifier><identifier>DOI: 10.1124/jpet.110.173187</identifier><identifier>PMID: 20829393</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Active Transport, Cell Nucleus - drug effects ; Active Transport, Cell Nucleus - physiology ; Analgesics, Opioid - metabolism ; Aryl Hydrocarbon Hydroxylases - genetics ; Aryl Hydrocarbon Hydroxylases - metabolism ; Buprenorphine - metabolism ; Buprenorphine - pharmacology ; Cytochrome P-450 CYP2B6 ; Cytochrome P-450 CYP3A - genetics ; Cytochrome P-450 CYP3A - metabolism ; Diprenorphine - metabolism ; Diprenorphine - pharmacology ; Gene Expression - drug effects ; Gene Expression - genetics ; Genes, Reporter - genetics ; Hep G2 Cells ; Hepatocytes - drug effects ; Hepatocytes - metabolism ; Humans ; Metabolism, Transport, and Pharmacogenomics ; Oxidoreductases, N-Demethylating - genetics ; Oxidoreductases, N-Demethylating - metabolism ; Pregnane X Receptor ; Receptors, Cytoplasmic and Nuclear - agonists ; Receptors, Cytoplasmic and Nuclear - antagonists &amp; inhibitors ; Receptors, Cytoplasmic and Nuclear - genetics ; Receptors, Cytoplasmic and Nuclear - metabolism ; Receptors, Steroid - agonists ; Receptors, Steroid - antagonists &amp; inhibitors ; Receptors, Steroid - genetics ; Receptors, Steroid - metabolism ; Transfection</subject><ispartof>The Journal of pharmacology and experimental therapeutics, 2010-12, Vol.335 (3), p.562-571</ispartof><rights>2010 American Society for Pharmacology and Experimental Therapeutics</rights><rights>Copyright © 2010 by The American Society for Pharmacology and Experimental Therapeutics</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c533t-cea9b5051af39731c2d1f88d631aef456951e46806faea4de646869acffab89e3</citedby><cites>FETCH-LOGICAL-c533t-cea9b5051af39731c2d1f88d631aef456951e46806faea4de646869acffab89e3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,776,780,881,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/20829393$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Li, Linhao</creatorcontrib><creatorcontrib>Hassan, Hazem E.</creatorcontrib><creatorcontrib>Tolson, Antonia H.</creatorcontrib><creatorcontrib>Ferguson, Stephen S.</creatorcontrib><creatorcontrib>Eddington, Natalie D.</creatorcontrib><creatorcontrib>Wang, Hongbing</creatorcontrib><title>Differential Activation of Pregnane X Receptor and Constitutive Androstane Receptor by Buprenorphine in Primary Human Hepatocytes and HepG2 Cells</title><title>The Journal of pharmacology and experimental therapeutics</title><addtitle>J Pharmacol Exp Ther</addtitle><description>Buprenorphine is a partial μ-opioid receptor agonist used for the treatment of opioid dependence that has several advantages over methadone. The principal route of buprenorphine disposition has been well established; however, little is known regarding the potential for buprenorphine to influence the metabolism and clearance of other drugs by affecting the expression of drug-metabolizing enzymes (DMEs). Here, we investigate the effects of buprenorphine on the activation of pregnane X receptor (PXR) and constitutive androstane receptor (CAR), as well as the induction of DMEs, in both HepG2 cells and human primary hepatocytes (HPHs). In HepG2 cells, buprenorphine significantly increased human PXR-mediated CYP2B6 and CYP3A4 reporter activities. CYP2B6 reporter activity was also enhanced by buprenorphine in HepG2 cells cotransfected with a chemical-responsive human CAR variant. Real-time reverse transcription-polymerase chain reaction analysis revealed that buprenorphine strongly induced CYP3A4 expression in both PXR- and CAR-transfected HepG2 cells. However, treatment with the same concentrations of buprenorphine in HPHs resulted in literally no induction of CYP3A4 or CYP2B6 expression. Further studies indicated that buprenorphine could neither translocate human CAR to the nucleus nor activate CYP2B6/CYP3A4 reporter activities in transfected HPHs. Subsequent experiments to determine whether the differential response was due to buprenorphine’s metabolic stability revealed a dramatically differential rate of elimination for buprenorphine between HPHs and HepG2 cells. Taken together, these studies indicate that metabolic stability of buprenorphine defines the differential induction of DMEs observed in HepG2 and HPHs, and the results obtained from PXR and CAR reporter assays in immortalized cell line require cautious interpretation.</description><subject>Active Transport, Cell Nucleus - drug effects</subject><subject>Active Transport, Cell Nucleus - physiology</subject><subject>Analgesics, Opioid - metabolism</subject><subject>Aryl Hydrocarbon Hydroxylases - genetics</subject><subject>Aryl Hydrocarbon Hydroxylases - metabolism</subject><subject>Buprenorphine - metabolism</subject><subject>Buprenorphine - pharmacology</subject><subject>Cytochrome P-450 CYP2B6</subject><subject>Cytochrome P-450 CYP3A - genetics</subject><subject>Cytochrome P-450 CYP3A - metabolism</subject><subject>Diprenorphine - metabolism</subject><subject>Diprenorphine - pharmacology</subject><subject>Gene Expression - drug effects</subject><subject>Gene Expression - genetics</subject><subject>Genes, Reporter - genetics</subject><subject>Hep G2 Cells</subject><subject>Hepatocytes - drug effects</subject><subject>Hepatocytes - metabolism</subject><subject>Humans</subject><subject>Metabolism, Transport, and Pharmacogenomics</subject><subject>Oxidoreductases, N-Demethylating - genetics</subject><subject>Oxidoreductases, N-Demethylating - metabolism</subject><subject>Pregnane X Receptor</subject><subject>Receptors, Cytoplasmic and Nuclear - agonists</subject><subject>Receptors, Cytoplasmic and Nuclear - antagonists &amp; inhibitors</subject><subject>Receptors, Cytoplasmic and Nuclear - genetics</subject><subject>Receptors, Cytoplasmic and Nuclear - metabolism</subject><subject>Receptors, Steroid - agonists</subject><subject>Receptors, Steroid - antagonists &amp; inhibitors</subject><subject>Receptors, Steroid - genetics</subject><subject>Receptors, Steroid - metabolism</subject><subject>Transfection</subject><issn>0022-3565</issn><issn>1521-0103</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2010</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kc9uEzEQxi0EomnhzA35BZb6z3q7viCFlDZIlYqqInGzJt5x62pjr2wnUh6DN8ZpIIJDT55P8_lnz3yEfODsE-eiPX-asNSqqgvJ-4tXZMaV4A3jTL4mM8aEaKTq1Ak5zfmJMd62nXxLTgTrhZZazsivS-8cJgzFw0jntvgtFB8DjY5-T_gQICD9Se_Q4lRiohAGuoghF1821Yt0HoYUc9nbjqbVjn7ZTBUa0_Toa8eHCvNrSDu63Kwh0CVOUKLdFczPyKqvBV3gOOZ35I2DMeP7P-cZ-XH19X6xbG5ur78t5jeNVVKWxiLolWKKg5O6Dm_FwF3fD53kgK5VnVYc265nnQOEdsCuik6DdQ5WvUZ5Rj4fuNNmtcbB1hUkGM10-KeJ4M3_neAfzUPcGqG1VEpVwPkBYOsCckJ3vMuZ2adj9unUqqrndOqNj_8-efT_jaMa9MGAdfCtx2Sy9RgsDj6hLWaI_kX4bzR7o8I</recordid><startdate>20101201</startdate><enddate>20101201</enddate><creator>Li, Linhao</creator><creator>Hassan, Hazem E.</creator><creator>Tolson, Antonia H.</creator><creator>Ferguson, Stephen S.</creator><creator>Eddington, Natalie D.</creator><creator>Wang, Hongbing</creator><general>Elsevier Inc</general><general>The American Society for Pharmacology and Experimental Therapeutics</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>5PM</scope></search><sort><creationdate>20101201</creationdate><title>Differential Activation of Pregnane X Receptor and Constitutive Androstane Receptor by Buprenorphine in Primary Human Hepatocytes and HepG2 Cells</title><author>Li, Linhao ; Hassan, Hazem E. ; Tolson, Antonia H. ; Ferguson, Stephen S. ; Eddington, Natalie D. ; Wang, Hongbing</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c533t-cea9b5051af39731c2d1f88d631aef456951e46806faea4de646869acffab89e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2010</creationdate><topic>Active Transport, Cell Nucleus - drug effects</topic><topic>Active Transport, Cell Nucleus - physiology</topic><topic>Analgesics, Opioid - metabolism</topic><topic>Aryl Hydrocarbon Hydroxylases - genetics</topic><topic>Aryl Hydrocarbon Hydroxylases - metabolism</topic><topic>Buprenorphine - metabolism</topic><topic>Buprenorphine - pharmacology</topic><topic>Cytochrome P-450 CYP2B6</topic><topic>Cytochrome P-450 CYP3A - genetics</topic><topic>Cytochrome P-450 CYP3A - metabolism</topic><topic>Diprenorphine - metabolism</topic><topic>Diprenorphine - pharmacology</topic><topic>Gene Expression - drug effects</topic><topic>Gene Expression - genetics</topic><topic>Genes, Reporter - genetics</topic><topic>Hep G2 Cells</topic><topic>Hepatocytes - drug effects</topic><topic>Hepatocytes - metabolism</topic><topic>Humans</topic><topic>Metabolism, Transport, and Pharmacogenomics</topic><topic>Oxidoreductases, N-Demethylating - genetics</topic><topic>Oxidoreductases, N-Demethylating - metabolism</topic><topic>Pregnane X Receptor</topic><topic>Receptors, Cytoplasmic and Nuclear - agonists</topic><topic>Receptors, Cytoplasmic and Nuclear - antagonists &amp; inhibitors</topic><topic>Receptors, Cytoplasmic and Nuclear - genetics</topic><topic>Receptors, Cytoplasmic and Nuclear - metabolism</topic><topic>Receptors, Steroid - agonists</topic><topic>Receptors, Steroid - antagonists &amp; inhibitors</topic><topic>Receptors, Steroid - genetics</topic><topic>Receptors, Steroid - metabolism</topic><topic>Transfection</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Li, Linhao</creatorcontrib><creatorcontrib>Hassan, Hazem E.</creatorcontrib><creatorcontrib>Tolson, Antonia H.</creatorcontrib><creatorcontrib>Ferguson, Stephen S.</creatorcontrib><creatorcontrib>Eddington, Natalie D.</creatorcontrib><creatorcontrib>Wang, Hongbing</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>The Journal of pharmacology and experimental therapeutics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Li, Linhao</au><au>Hassan, Hazem E.</au><au>Tolson, Antonia H.</au><au>Ferguson, Stephen S.</au><au>Eddington, Natalie D.</au><au>Wang, Hongbing</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Differential Activation of Pregnane X Receptor and Constitutive Androstane Receptor by Buprenorphine in Primary Human Hepatocytes and HepG2 Cells</atitle><jtitle>The Journal of pharmacology and experimental therapeutics</jtitle><addtitle>J Pharmacol Exp Ther</addtitle><date>2010-12-01</date><risdate>2010</risdate><volume>335</volume><issue>3</issue><spage>562</spage><epage>571</epage><pages>562-571</pages><issn>0022-3565</issn><eissn>1521-0103</eissn><abstract>Buprenorphine is a partial μ-opioid receptor agonist used for the treatment of opioid dependence that has several advantages over methadone. The principal route of buprenorphine disposition has been well established; however, little is known regarding the potential for buprenorphine to influence the metabolism and clearance of other drugs by affecting the expression of drug-metabolizing enzymes (DMEs). Here, we investigate the effects of buprenorphine on the activation of pregnane X receptor (PXR) and constitutive androstane receptor (CAR), as well as the induction of DMEs, in both HepG2 cells and human primary hepatocytes (HPHs). In HepG2 cells, buprenorphine significantly increased human PXR-mediated CYP2B6 and CYP3A4 reporter activities. CYP2B6 reporter activity was also enhanced by buprenorphine in HepG2 cells cotransfected with a chemical-responsive human CAR variant. Real-time reverse transcription-polymerase chain reaction analysis revealed that buprenorphine strongly induced CYP3A4 expression in both PXR- and CAR-transfected HepG2 cells. However, treatment with the same concentrations of buprenorphine in HPHs resulted in literally no induction of CYP3A4 or CYP2B6 expression. Further studies indicated that buprenorphine could neither translocate human CAR to the nucleus nor activate CYP2B6/CYP3A4 reporter activities in transfected HPHs. Subsequent experiments to determine whether the differential response was due to buprenorphine’s metabolic stability revealed a dramatically differential rate of elimination for buprenorphine between HPHs and HepG2 cells. Taken together, these studies indicate that metabolic stability of buprenorphine defines the differential induction of DMEs observed in HepG2 and HPHs, and the results obtained from PXR and CAR reporter assays in immortalized cell line require cautious interpretation.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>20829393</pmid><doi>10.1124/jpet.110.173187</doi><tpages>10</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0022-3565
ispartof The Journal of pharmacology and experimental therapeutics, 2010-12, Vol.335 (3), p.562-571
issn 0022-3565
1521-0103
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2993555
source MEDLINE; Alma/SFX Local Collection
subjects Active Transport, Cell Nucleus - drug effects
Active Transport, Cell Nucleus - physiology
Analgesics, Opioid - metabolism
Aryl Hydrocarbon Hydroxylases - genetics
Aryl Hydrocarbon Hydroxylases - metabolism
Buprenorphine - metabolism
Buprenorphine - pharmacology
Cytochrome P-450 CYP2B6
Cytochrome P-450 CYP3A - genetics
Cytochrome P-450 CYP3A - metabolism
Diprenorphine - metabolism
Diprenorphine - pharmacology
Gene Expression - drug effects
Gene Expression - genetics
Genes, Reporter - genetics
Hep G2 Cells
Hepatocytes - drug effects
Hepatocytes - metabolism
Humans
Metabolism, Transport, and Pharmacogenomics
Oxidoreductases, N-Demethylating - genetics
Oxidoreductases, N-Demethylating - metabolism
Pregnane X Receptor
Receptors, Cytoplasmic and Nuclear - agonists
Receptors, Cytoplasmic and Nuclear - antagonists & inhibitors
Receptors, Cytoplasmic and Nuclear - genetics
Receptors, Cytoplasmic and Nuclear - metabolism
Receptors, Steroid - agonists
Receptors, Steroid - antagonists & inhibitors
Receptors, Steroid - genetics
Receptors, Steroid - metabolism
Transfection
title Differential Activation of Pregnane X Receptor and Constitutive Androstane Receptor by Buprenorphine in Primary Human Hepatocytes and HepG2 Cells
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-08T00%3A55%3A33IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Differential%20Activation%20of%20Pregnane%20X%20Receptor%20and%20Constitutive%20Androstane%20Receptor%20by%20Buprenorphine%20in%20Primary%20Human%20Hepatocytes%20and%20HepG2%20Cells&rft.jtitle=The%20Journal%20of%20pharmacology%20and%20experimental%20therapeutics&rft.au=Li,%20Linhao&rft.date=2010-12-01&rft.volume=335&rft.issue=3&rft.spage=562&rft.epage=571&rft.pages=562-571&rft.issn=0022-3565&rft.eissn=1521-0103&rft_id=info:doi/10.1124/jpet.110.173187&rft_dat=%3Cpubmed_cross%3E20829393%3C/pubmed_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/20829393&rft_els_id=S0022356524461235&rfr_iscdi=true